Morgan Stanley urges pipeline-weak big pharma to exit research
This article was originally published in Scrip
Executive Summary
Big pharma's hopes on thriving over the coming years depend on its ability to refocus its business strategies on in-licensed products, rather than in-house research, according to Morgan Stanley analysts.